BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Leronlimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Leronlimab\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07553338-1012@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Leronlimab: Phase 2 readout est. (NCT07553338)
DESCRIPTION:Leronlimab\, phase 2\, Alzheimer's Disease.\nStudy: Safety Asse
 ssment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's D
 isease\nEstimated primary completion: November 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/leronlimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07553338
URL:https://assetmemo.bio/drug/leronlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06699836-1012@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Leronlimab: Phase 2 readout est. (NCT06699836)
DESCRIPTION:Leronlimab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: CL
 OVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor
  Enriched Regimen\nEstimated primary completion: January 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/leronlimab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06699836
URL:https://assetmemo.bio/drug/leronlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07842965-1012@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20280202
DTEND;VALUE=DATE:20280203
SUMMARY:Leronlimab: Phase 1 readout est. (NCT07842965)
DESCRIPTION:Leronlimab\, phase 1.\nStudy: CCR5 Targeting Leronlimab in Comb
 ination With Hepatic Arterial Infusion Floxuridine and Systemic Therapy fo
 r the Treatment of Colorectal Cancer Liver Metastases\, CHAMP Trial\nEstim
 ated primary completion: 2 February 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/leronlimab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07842965
URL:https://assetmemo.bio/drug/leronlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
